Us7220852b1 patent. US Patent for Coronavirus Patent (Patent # 10,130,701 issued November 20, 2018)

C.I.A. PATENT US7220852B1

us7220852b1 patent

Methods of alignment of sequences for comparison are well known in the art. Typically, a naturally occurring immunoglobulin has heavy H chains and light L chains interconnected by disulfide bonds. When administered to a subject, a dosage will generally be used that will achieve target tissue concentrations that has been shown to achieve a desired in vitro effect. In humans, this class or isotype includes IgA 1 and IgA 2. While the differing orientations of the N-terminal helix in the two complexes suggests a degree of structural plasticity, residues of the hinge and C-terminal helix in the two complexes are highly conserved and are involved in the most critical interactions with the antibody. The cassettes can be transferred into the chosen host cell by well-known methods such as transformation or electroporation for E.

Nächster

EP1694829B1

us7220852b1 patent

A variety of aqueous carriers can be used, for example, buffered saline and the like. For example, an antibody that specifically binds gp41, that was originally IgM may be class switched to an IgG. The linkage can be by chemical or recombinant means. There's no invention of the virus itself because if you read it. As of now, however, there is no evidence that the lab is the source of the outbreak.

Nächster

C.I.A. PATENT US7220852B1

us7220852b1 patent

If desired, the nucleic acid can be further manipulated to create other antibody fragments, also as described herein. The cassettes can be suitable for replication and integration in either prokaryotes or eukaryotes. Therefore, in these circumstances, immunoconjugates will include linkages that are cleavable in the vicinity of the target site. In some examples, the disclosed antibodies are oligomers of antibodies, such as dimers, trimers, tetramers, pentamers, hexamers, septamers, octomers and so on. Effector molecules, such as therapeutic, diagnostic, or detection moieties can be linked to an antibody of interest, using any number of means known to those of skill in the art. Pallansch Anthony Sanchez Suxiang Tong Sherif R. The invention will now be further described by way of Examples, which are meant to serve to assist one of ordinary skill in the art in carrying out the invention and are not intended in any way to limit the scope of the invention.

Nächster

C.I.A. PATENT US7220852B1

us7220852b1 patent

Effector molecule: The portion of a chimeric molecule that is intended to have a desired effect on a cell to which the chimeric molecule is targeted. Epitopes can be formed both from contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of a protein. The nucleotide sequence may comprise the substitutions G18114C and T19047A. The present invention also provides a method for producing a vaccine according to the seventh aspect of the invention, which comprises the step of infecting a cell according to the sixth aspect of the invention with a coronavirus according to the first aspect of the invention. Anti-retroviral agent: An agent that specifically inhibits a retrovirus from replicating or infecting cells.

Nächster

PolitiFact

us7220852b1 patent

Identity comparisons can be conducted by eye, or more usually, with the aid of readily available sequence comparison programs. In yet another embodiment, a high binding affinity is measured by a competition radioimmunoassay. It is understood that all progeny may not be identical to the parental cell since there may be mutations that occur during replication. The recombining virus is one suitable to allow homologous recombination between its genome and the plasmid. The compositions may contain pharmaceutically acceptable auxiliary substances as required to approximate physiological conditions such as pH adjusting and buffering agents, toxicity adjusting agents and the like, for example, sodium acetate, sodium chloride, potassium chloride, calcium chloride, sodium lactate and the like. Monoclonal antibodies are produced by methods known to those of skill in the art, for instance by making hybrid antibody-forming cells from a fusion of myeloma cells with immune spleen cells.

Nächster

US Patent Application for NEUTRALIZING GP41 ANTIBODIES AND THEIR USE Patent Application (Application #20180002406 issued January 4, 2018)

us7220852b1 patent

Often, functional heterologous proteins from E. Both constitutive and inducible promoters are included see for example, Bitter et al. For example, for the bimolecular interaction of an antibody such as one disclosed herein and an antigen such as gp41 it is the concentration of the individual components of the bimolecular interaction divided by the concentration of the complex. The linker is capable of forming covalent bonds to both the antibody and to the effector molecule. Since that time the virus has crept towards Europe. In example, the cell is also contacted with an effective amount of an additional agent, such as anti-viral agent. Excess oxidized glutathione or other oxidizing low molecular weight compounds can be added to the refolding solution after the redox-shuffling is completed.

Nächster

PolitiFact

us7220852b1 patent

. Methods for producing scFvs are known in the art see Whitlow et al. Proteins of greater length may be synthesized by condensation of the amino and carboxyl termini of shorter fragments. In some embodiments, the control is a sample obtained from a healthy patient. The fragments are then size-separated by electrophoresis a polyacrylamide gel, or in a narrow glass tube capillary filled with a viscous polymer. They also at what point the virus becomes contagious.

Nächster

US7220852B1

us7220852b1 patent

In some circumstances, it is desirable to free the effector molecule from the antibody when the immunoconjugate has reached its target site. The linkage can be either by chemical or recombinant means. The amount and timing of administration are at the discretion of the treating physician to achieve the desired purposes. An antibody may be labeled with a magnetic agent, such as gadolinium. For instance, parenteral formulations usually include injectable fluids that include pharmaceutically and physiologically acceptable fluids such as water, physiological saline, balanced salt solutions, aqueous dextrose, glycerol or the like as a vehicle.

Nächster